These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23416862)

  • 1. Tivozanib in renal cell carcinoma.
    Figlin R
    Clin Adv Hematol Oncol; 2013 Jan; 11(1):43-5. PubMed ID: 23416862
    [No Abstract]   [Full Text] [Related]  

  • 2. Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.
    Mehta A; Sonpavde G; Escudier B
    Future Oncol; 2014 Aug; 10(11):1819-26. PubMed ID: 25325825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).
    Haberkorn BC; Eskens FA
    Future Oncol; 2013 Jan; 9(1):13-20. PubMed ID: 23252559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tivozanib for the treatment of metastatic renal cancer.
    Wong HH; Eisen T
    Expert Rev Anticancer Ther; 2013 Jun; 13(6):649-60. PubMed ID: 23773100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma.
    Cowey CL
    Drug Des Devel Ther; 2013; 7():519-27. PubMed ID: 23818763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deal watch: Aveo and Astellas to develop VEGF inhibitor for renal cell carcinoma.
    Nat Rev Drug Discov; 2011 Apr; 10(4):248. PubMed ID: 21455225
    [No Abstract]   [Full Text] [Related]  

  • 7. Tivozanib: practical implications for renal cell carcinoma and other solid tumors.
    Berge EM; Bowles DW; Flaig TW; Lam ET; Jimeno A
    Drugs Today (Barc); 2013 May; 49(5):303-15. PubMed ID: 23724410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tivozanib: a new treatment option for renal cell carcinoma.
    Saes L; Eskens FALM
    Drugs Today (Barc); 2017 Nov; 53(11):609-618. PubMed ID: 29451277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC.
    Wright KM
    Oncology (Williston Park); 2020 Jul; 34(7):257. PubMed ID: 32674211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress and contrasts of the development of tivozanib for therapy of kidney cancer.
    Gupta S; Fishman M
    Expert Opin Pharmacother; 2011 Dec; 12(18):2915-22. PubMed ID: 22098229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tivozanib for the treatment of renal cell carcinoma.
    Santoni M; Massari F; Piva F; Carrozza F; Di Nunno V; Cimadamore A; Martignetti A; Montironi R; Battelli N
    Expert Opin Pharmacother; 2018 Jun; 19(9):1021-1025. PubMed ID: 29851529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma.
    Jacob A; Shook J; Hutson TE
    Future Oncol; 2020 Oct; 16(28):2147-2164. PubMed ID: 32692256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tivozanib: First Global Approval.
    Kim ES
    Drugs; 2017 Nov; 77(17):1917-1923. PubMed ID: 28971328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study.
    Garnick MB
    J Clin Oncol; 2013 Oct; 31(30):3746-8. PubMed ID: 24019543
    [No Abstract]   [Full Text] [Related]  

  • 15. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.
    Nosov DA; Esteves B; Lipatov ON; Lyulko AA; Anischenko AA; Chacko RT; Doval DC; Strahs A; Slichenmyer WJ; Bhargava P
    J Clin Oncol; 2012 May; 30(14):1678-85. PubMed ID: 22493422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer.
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):512-3. PubMed ID: 26351813
    [No Abstract]   [Full Text] [Related]  

  • 17. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus.
    Vázquez Estévez S; Anido U; Lázaro M; Fernández O; Fernández Núñez N; de Dios Álvarez N; Varela V; Campos Balea B; Agraso S; Areses MC; Iglesias L; Blanco M; Maciá S; Anton Aparicio LM
    Clin Transl Oncol; 2020 Sep; 22(9):1565-1579. PubMed ID: 32062835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
    Albiges L; Salem M; Rini B; Escudier B
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.
    Pal SK; Escudier BJ; Atkins MB; Hutson TE; Porta C; Verzoni E; Needle MN; Powers D; McDermott DF; Rini BI
    Eur Urol; 2020 Dec; 78(6):783-785. PubMed ID: 32938569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review.
    Schwartz C; Pfanzelter N; Kuzel TM
    Clin Genitourin Cancer; 2017 Oct; 15(5):e903-e906. PubMed ID: 28624319
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.